Hikma’s Injectables Business Expands As It Completes Custopharm Acquisition

Completion Of $425m Deal Comes Shortly After FTC Approved The Transaction

Hikma has completed its acquisition of Custopharm, expanding its US injectables business as the company continues to look for more deals.

Complete Word Jigsaw Pieces
Hikma has now completed its deal to acquire Custopharm • Source: Cagkan Sayin / Alamy Stock Photo

Hikma has now completed its acquisition of US sterile injectables specialist Custopharm from Water Street Healthcare Partners, in a deal that promises to further expand its US injectables business.

The transaction – which is worth up to $425m, comprising a $375m upfront purchase price and a further $50m in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business